UTHR
HealthcareUnited Therapeutics Corporation · Biotechnology · $22B
What is United Therapeutics Corporation?
United Therapeutics is a large-cap biotechnology company focused on developing and commercializing therapies for patients with chronic, life-threatening diseases — particularly pulmonary arterial hypertension.
The company generates revenue primarily through a portfolio of PAH therapies delivered via injection, inhalation, and oral tablet. It also markets a treatment for high-risk neuroblastoma and maintains an active pipeline targeting gene therapy and next-generation drug delivery systems for serious lung conditions.
Founded in 1999 and headquartered in Silver Spring, Maryland.
- Tyvaso — inhaled treprostinil for PAH and PH-ILD
- Remodulin — continuous infusion therapy for PAH
- Orenitram — oral treprostinil tablet for PAH
- Unituxin — monoclonal antibody for high-risk neuroblastoma
Is UTHR a Good Stock to Buy?
UQS Score rates UTHR as Good overall.
United Therapeutics earns Strong marks on both Quality and Risk, reflecting a well-managed balance sheet and stable cash generation relative to sector peers. These pillars suggest the business carries less financial fragility than many biotechs of comparable size.
The Moat and Growth pillars both register as Neutral, indicating the company's competitive durability and expansion trajectory are in line with — but not clearly ahead of — sector norms.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does UTHR pay dividends?
No — United Therapeutics Corporation does not currently pay a dividend.
United Therapeutics does not currently pay a dividend. For a biotech with an active pipeline — including gene therapy programs and new drug delivery platforms — retaining capital to fund research and development is a common and strategically logical choice.
When does UTHR report earnings?
United Therapeutics reports earnings on a quarterly cadence, typical for US-listed equities.
The company's revenue base is anchored by its PAH franchise, which has shown durability across recent reporting periods. Pipeline progress and label expansions for existing therapies have been key narrative drivers in recent quarters.
For the most recent quarter's results, visit United Therapeutics' investor relations page directly.
UTHR Price History
+180.8% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in United Therapeutics Corporation?
Based on United Therapeutics Corporation's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
Frequently Asked Questions
What does United Therapeutics do?
United Therapeutics is a biotechnology company that develops and sells therapies for pulmonary arterial hypertension and other serious diseases. Its commercial portfolio includes inhaled, injectable, and oral treatments, along with a therapy for high-risk neuroblastoma. The company also has an active pipeline in gene therapy and next-generation drug delivery.
Does UTHR pay dividends?
No, United Therapeutics does not pay a dividend. The company reinvests its capital into pipeline development, including gene therapy programs and new formulations of existing PAH treatments.
When does UTHR report earnings?
United Therapeutics reports on a standard quarterly schedule. For confirmed dates and the latest results, check the investor relations section of the company's official website.
Is UTHR a good stock to buy?
UQS Score rates UTHR as Good overall, with Strong marks on Quality and Risk. Whether it fits your portfolio depends on your goals and risk tolerance. The full pillar breakdown is available to Pro members on UQS Score.
Is UTHR overvalued?
The UQS Valuation pillar for UTHR is rated Good, suggesting the stock is not trading at a significant premium relative to its quality profile. The complete valuation analysis is available with a Pro membership.
What is UTHR's market cap bracket?
United Therapeutics is classified as a large-cap company, placing it among the larger publicly traded biotechnology firms by market value.
Is UTHR a long-term quality investment?
From a quality standpoint, UTHR's Strong Risk and Quality pillar ratings suggest a more durable business profile than many biotech peers. Long-term suitability depends on how the pipeline matures and whether the PAH franchise sustains its competitive position over time.
What sector does UTHR belong to?
United Therapeutics operates in the Healthcare sector, specifically within biotechnology. Its focus on rare and chronic diseases — particularly pulmonary hypertension — places it in a specialized niche within that broader sector.
Unlock Full UTHR Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete UQS pillar scores across Quality, Moat, Growth, Risk, and Valuation
- ✓Access detailed financial metrics behind each pillar rating
- ✓Compare UTHR against sector peers on a standardized scoring framework
- ✓Track score changes over time as new data is released
Pro Analysis
UTHR — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| Aug 8, 2026 | 43.4 | 58.0 | 53.0 | 26.5 | 69.2 | 0.0 | -25.7 |
| Aug 4, 2026 | 69.1 | 83.3 | 53.0 | 46.9 | 100.0 | 70.6 | +0.2 |
| Aug 1, 2026 | 68.9 | 83.2 | 53.0 | 46.9 | 100.0 | 70.1 | 0.0 |
| Jul 30, 2026 | 68.9 | 83.2 | 53.0 | 46.9 | 100.0 | 69.9 | +0.1 |
| Jul 29, 2026 | 68.8 | 83.1 | 53.0 | 46.9 | 100.0 | 69.6 | -0.1 |
| Jul 27, 2026 | 68.9 | 83.1 | 53.0 | 46.9 | 100.0 | 69.8 | -0.3 |
| Jul 24, 2026 | 69.2 | 83.1 | 53.0 | 46.8 | 100.0 | 72.2 | -0.1 |
| Jul 23, 2026 | 69.3 | 83.2 | 53.0 | 46.8 | 100.0 | 72.3 | +0.1 |
| Jul 22, 2026 | 69.2 | 83.0 | 53.0 | 47.1 | 100.0 | 71.9 | -0.1 |
| Jul 21, 2026 | 69.3 | 83.1 | 53.0 | 47.1 | 100.0 | 72.3 | -0.1 |
UTHR — Pillar Breakdown
Quality
— 58.0/100 (25%)United Therapeutics Corporation shows solid profitability with healthy returns on capital and reasonable margins.
How effectively capital is deployed to generate returns.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 26.5/100 (20%)United Therapeutics Corporation faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 69.2/100 (15%)United Therapeutics Corporation maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)United Therapeutics Corporation appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 53/100 (25%)United Therapeutics Corporation possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for UTHR.
Score Composition
Financial Data
More Stock Analysis
How is the UTHR UQS Score Calculated?
The UQS (Unified Quality Score) for United Therapeutics Corporation is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses United Therapeutics Corporation's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether United Therapeutics Corporation is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.